CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian mark ...
Pagination iv, 103 p. : ill. (some col.), maps, ports. ; 30 cm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback